Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in May. Read more >>
Knowing the enormous utility costs associated with running a science facility, Georgetown’s Energy and Utilities department invited Aircuity to evaluate how its platform could help reduce energy consumption while improving lab safety. Read more >>
With Toys ‘R’ Us shutting down their 735 stores in 2018, millennial parents have been finding new ways to encourage playtime for their children (besides the endless Amazon Prime deliveries!)—and many have looked no further than to kid subscription boxes. Read more >>
Members of the Boston Harbor Angels attended the Boston Red Sox vs. Seattle Mariners game on Friday, May 10, 2019 at Boston’s Fenway Park. The event was a collaboration between Boston Harbor Angels and The Boston Harbor Group.
The Boston Red Sox Welcome for Boston Harbor Angels and The Boston Harbor Group
The Boston Red Sox were victorious, beating the Seattle Mariners 14-1. Congrats!
About The Boston Harbor GroupOur mission is to understand you and your priorities. To take the time, to […]
To make life easier for their customers, many businesses are adopting the subscription business model. From consumer goods and hardware to eCommerce and internet of things (IoT), innovators are allowing shoppers to have products and offerings regularly delivered to them. From Perennial to Green Piñata Toys, eCommerce innovators are tapping into the subscription business model to deliver goods to customers on a recurring basis. Read more >>
TetraGenetics, a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders, announced today the addition of three new board members: Alison Taunton-Rigby Ph.D., OBE, Ellen Baron Ph.D. and Daniel Grau M. Phil. Read more >>
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic SclerosisZiad
Corbus Pharmaceuticals Holdings, Inc. today announced the completion of subject enrollment in RESOLVE-1, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of systemic sclerosis (SSc). The Company expects to report topline results from this study in the summer of 2020. These data are anticipated to support an initial marketing application for lenabasum. Read more >>
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with NeuroMuscular Orthotics Pty Ltd (NMO) with the goal of offering MyoPro across Australia and New Zealand. Read more >>
Carbonite, Inc., a leader in cloud-based data protection, will showcase the Carbonite Data Protection Platform at Dell Technologies World, April 29th – May 2nd 2019 in Las Vegas, Nevada. Read more >>